For excellence in diagnostics
– We’re bound to deliver
Medix Biochemica is a Finnish biotechnology company that develops, produces and markets monoclonal antibodies, antibody services and antigens for IVD industry as well as diagnostic rapid tests for human healthcare worldwide.
Business Activities
MedixMAB™ Antibodies & MedixAntigens
When we started the industrial-scale manufacturing of monoclonal antibodies over 30 years ago, we created a new paradigm for the antibody industry. Now our product range covers monoclonal antibodies and antigens for a variety of markers.
MedixMAB™ Contract Manufacturing
We offer a highly cost-effective service for in vitro monoclonal antibody and recombinant antigen production. Our customised turnkey contract manufacturing service makes antibody and antigen production both effortless and worry-free, with our fully certified quality control system.
Actim® Rapid Tests
Actim® Rapid Tests give results within minutes. They are specifically developed for use at point-of-care and in medical emergencies when quick and accurate diagnosis can make all the difference.
Our core competencies are
at the heart of everything we do
- Flexible production – from milligrams to hundreds of grams
- Constant quality – from batch to batch
- Quick and accurate deliveries globally
- Competitive pricing
Standing behind the quality
- CUSTOMER SATISFACTION
Our products and operations meet the needs and expectations of our customers. - COMMITMENT TO QUALITY
We are committed to high quality and pro activity in activities at all levels, we continuously improve of our operations and skills. - SAFE AND EFFECTIVE PRODUCTS
We develop products to the diagnostic field, which are reliable, suitable for the intended use, safe and effective and their performance is scientifically justified. - COMPLIANCE
We comply with the regulatory requirements and standards relevant to our field of business.
Quality management system
Company Milestones
Medix Biochemica is proud to say that we are one of the first companies in the world to produce monoclonal antibodies, starting only three years after Köhler and Milstein published their Nobel Prize winning work on the subject. Medix Biochemica was established in 1985 to meet the growing demand for developing and producing monoclonal antibodies.
1959 Minerva Foundation founded
1964 Medix Ltd. founded
1970 Reagent manufacturing established
1979 Manufacturing of monoclonal antibodies established
1985 Medix Biochemica founded
1990 Rapid test manufacturing established in Joensuu factory
1994 First Actim tests released
2003 ISO 13485 compliance
2006 FDA QSR compliance
2015 New facilities in Espoo
2016 Medix Biochemica China established
2018 Medix Biochemica USA established
2019 Lee Biosolutions acquired
2020 Biostride Inc. acquired
2020 EastCoast Bio acquired
Career with us!
Medix Biochemica employs over 180 highly trained professionals. Review the open positions and apply online.
If you are interested in becoming one of us, please click the following link to see our open vacancies: Open positions and applications and apply for positions online. If there are not any vacancies that suit your interest, you can send us an open application.
Contact Us
Please don’t hesitate to contact us – we look forward to hearing from you!